ReviewCell death & disease2013
Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation.
Review in Cell death & disease, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Nonlinear duration-efficacy association of neoadjuvant PD-1/PD-L1 blockade with chemoradiotherapy in pMMR/MSS locally advanced rectal cancer: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Optimal Neoadjuvant Approach for Resectable Esophageal Cancer in the Era of Immunotherapy.International journal of cancer · 2026Article
- Development of combinatorial immunotherapy for patients with advanced gastric cancer from the perspective of immunosuppressive mechanisms in the tumor microenvironment.Fukushima journal of medical science · 2026Review
- Late-phase strategies to overcome limitations of PD-1/PD-L1 therapy: a clinical development trajectory through 2030.Frontiers in oncology · 2026Review
- Diagnosing Complete Response to Preoperative Chemoradiation in Esophageal Cancer Using Dynamic Contrast-Enhanced MRI Response Criteria.Korean journal of radiology · 2025Article
- Radiotherapy as salvage therapy and an adjunct to immunotherapy: exploring local and abscopal mechanisms to overcome immunotherapy resistance: a narrative review.Translational lung cancer research · 2025Review
- Review
- Efficacy and safety analysis of immune checkpoint inhibitor rechallenge therapy in locally advanced and advanced non-small cell lung cancer: a retrospective study.Journal of thoracic disease · 2024Article
- Enhanced Chemo-Immunotherapy Strategy Utilizing Injectable Thermosensitive Hydrogel for The Treatment of Diffuse Peritoneal Metastasis in Advanced Colorectal Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Bioinformatics analysis of prognosis and immune microenvironment of immunological cell death-related gemcitabine-resistance genes in bladder cancer.Translational andrology and urology · 2022Article
- Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes.Frontiers in pharmacology · 2022Review
- A Proposed Link Between Acute Thymic Involution and Late Adverse Effects of Chemotherapy.Frontiers in immunology · 2022Article
- Tumor-Associated Macrophages: Combination of Therapies, the Approach to Improve Cancer Treatment.International journal of molecular sciences · 2021Review
- Radiation therapy enhanced therapeutic efficacy of anti-PD1 against gastric cancer.Journal of radiation research · 2020Article
- Predicting therapeutic efficacy of endocrine therapy for stage IV breast cancer by tumor-infiltrating lymphocytes.Molecular and clinical oncology · 2020Article
- Innate immune checkpoints for cancer immunotherapy: expanding the scope of non T cell targets.Annals of translational medicine · 2020Article
- Review
- Induction chemoradiotherapy including docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer.Esophagus : official journal of the Japan Esophageal Society · 2020Article
- Ki67 expression and localization of T cells after neoadjuvant therapies as reliable predictive markers in rectal cancer.Cancer science · 2020Article
- HMGB1 in Radiotherapy: A Two Headed Signal Regulating Tumor Radiosensitivity and Immunity.OncoTargets and therapy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemoradiotherapy can induce immunogenic cell death, triggering danger signals such as high-mobility group box 1 protein, and resulting in T-cell immunity. This concept can potentially be harnessed for clinical therapy to enhance tumor-specific immunity. There is however limited information to translate this theory directly in a clinical setting. In this review, we will discuss and summarize molecular and cellular mechanisms underlying immunogenic tumor cell death induced by chemoradiotherapy, with emphasis on a clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.